Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

IGFBP2 as an Immunohistochemical Marker for Prostatic Adenocarcinoma

IGFBP2 as an Immunohistochemical Marker for Prostatic Adenocarcinoma RESEARCH ARTICLE IGFBP2 as an Immunohistochemical Marker for Prostatic Adenocarcinoma Andrea Ambrosini-Spaltro, MD,* Anna Farnedi, BSc, PhD,* Rodolfo Montironi, MD,w and Maria P. Foschini, MD* nsulin-like growth factors (IGFs) and insulin-like Aim: The aim of the study was to evaluate the immunohisto- Igrowth factor binding proteins (IGFBPs) play a central chemical expression of insulin-like growth factor binding role in cellular growth, and in normal and neoplastic protein 2 (IGFBP2) in normal epithelium, high-grade prostatic development. intraepithelial neoplasia (HG-PIN), and prostatic adenocarci- IGFBP2 has been shown to be hyperexpressed in noma (PAc), in patients hormonally untreated and in those many human malignancies, including ovarian carcino- 1 2 3 having undergone complete androgen ablation. ma, colorectal carcinoma, hepatocellular carcinoma, and neuroblastoma. In addition, IGFBP2 has been Materials and Methods: IGFBP2 expression was evaluated in shown to be highly expressed in glioblastoma, both gene- PAc, HG-PIN, and normal-appearing epithelium in 40 radical tically and immunohistochemically. IGFBP2 has even prostatectomies from hormonally untreated patients and 10 been considered to be a therapeutic target in neo- radical prostatectomies from patients under complete androgen plastic cell lines derived from breast carcinoma, both ablation before surgery. The study also included the initial 6 7 directly and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

IGFBP2 as an Immunohistochemical Marker for Prostatic Adenocarcinoma

Download PDF
11 pages

Loading next page...
 
/lp/wolters-kluwer-health/igfbp2-as-an-immunohistochemical-marker-for-prostatic-adenocarcinoma-tZNgdgWNZP

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2011 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e3128052936
pmid
21304397
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE IGFBP2 as an Immunohistochemical Marker for Prostatic Adenocarcinoma Andrea Ambrosini-Spaltro, MD,* Anna Farnedi, BSc, PhD,* Rodolfo Montironi, MD,w and Maria P. Foschini, MD* nsulin-like growth factors (IGFs) and insulin-like Aim: The aim of the study was to evaluate the immunohisto- Igrowth factor binding proteins (IGFBPs) play a central chemical expression of insulin-like growth factor binding role in cellular growth, and in normal and neoplastic protein 2 (IGFBP2) in normal epithelium, high-grade prostatic development. intraepithelial neoplasia (HG-PIN), and prostatic adenocarci- IGFBP2 has been shown to be hyperexpressed in noma (PAc), in patients hormonally untreated and in those many human malignancies, including ovarian carcino- 1 2 3 having undergone complete androgen ablation. ma, colorectal carcinoma, hepatocellular carcinoma, and neuroblastoma. In addition, IGFBP2 has been Materials and Methods: IGFBP2 expression was evaluated in shown to be highly expressed in glioblastoma, both gene- PAc, HG-PIN, and normal-appearing epithelium in 40 radical tically and immunohistochemically. IGFBP2 has even prostatectomies from hormonally untreated patients and 10 been considered to be a therapeutic target in neo- radical prostatectomies from patients under complete androgen plastic cell lines derived from breast carcinoma, both ablation before surgery. The study also included the initial 6 7 directly and

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Jul 1, 2011

There are no references for this article.